tubulis.com
Get leads like Tubulis — and thousands more
Build targeted lists by tech stack, traffic, and more
Tubulis: The Biotech Weaponizing ADCs
How Munich's precision oncology play is redefining antibody-drug conjugates
In the brutal landscape of biotech, Tubulis isn't just building drugs—they're engineering precision weapons. While competitors flood the market with generic antibodies, this Munich-based team is quietly perfecting the chemistry of targeted cancer destruction.
"They're not chasing biotech hype cycles—they're building the infrastructure for the next generation of cancer therapies."
The ADC Advantage
Tubulis operates in the high-stakes world of Antibody Drug Conjugates (ADCs)—a $10B+ market where precision is everything. Their technology platform (TUB-030) addresses the Achilles' heel of ADCs: stability. While traditional ADCs leak toxins into healthy tissue, Tubulis' conjugation chemistry keeps the payload locked until it hits the tumor. This isn't incremental improvement—it's solving the fundamental toxicity problem that has plagued ADCs for decades.
The Metrics Don't Lie
With 13,486 monthly visits and a global rank of #1.7M, Tubulis isn't a traffic play—it's a specialist's destination. The 40% direct traffic is telling: investors, partners, and researchers are bookmarking the site, not stumbling upon it. The 710 monthly searches for 'tubulis' alone signals a dedicated following in a niche where broad awareness is irrelevant. This is the footprint of a company building for the biotech elite, not the general public.
The tech stack reveals their modern approach: Tailwind CSS, jQuery, and Google Analytics suggest a lean, agile digital presence focused on function over flash. Unlike bloated pharma sites, Tubulis.com loads fast and converts—exactly what you'd expect from a company that prioritizes R&D over marketing fluff. Their social presence on Twitter and LinkedIn is disciplined, not desperate—sharing science, not hype.
- Dominik Schumacher's leadership: A PhD in biochemistry steering a $216M ship toward clinical inflection points
- Munich ecosystem advantage: Access to Germany's deep biotech talent pool and EU regulatory pathways
- Pipeline focus: TUB-030 (HER2-targeting) and TUB-040 (Nectin-4) represent two shots on goal in high-value oncology indications
The Biotech Blueprint
Tubulis isn't building a brand—it's building a platform. For founders, the lesson is clear: in deep tech, authority beats awareness. For investors, the $216M war chest buys a front-row seat to ADC evolution. For product teams, their site is a masterclass in serving the experts who actually matter. Watch this Munich machine.
What tech stack does Tubulis use?
How much traffic does Tubulis get?
Traffic & Engagement
Traffic Sources
Where is Tubulis's audience located?
What keywords does Tubulis rank for?
5 keywordsHow is Tubulis's SEO?
Meta Tags
Startseite - Tubulis
Reimagining Antibody Drug Conjugates NEWS October 30 Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M) October 19 Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025 October 15 Tubulis Raises €308 Million Series C to Accelerate Clinical Development of […]
H1 Tags
Schema Types
What is Tubulis's revenue?
Who works at Tubulis?
Loading leads...
What do customers think of Tubulis?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Tubulis
What is Tubulis's Revenue?
How fast is Tubulis growing?
What technologies does Tubulis use?
Who are Tubulis's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Tubulis?
Contact Information
Export tubulis.com Data
Download the complete tech stack, analytics, leads, and company data for tubulis.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About tubulis.com
Company Overview
tubulis.com Social Media
Contact tubulis.com
Phone Numbers
Technology Stack
tubulis.com uses 13 technologies across their website including Font Awesome, PHP, WordPress, and more.
Fonts
Font Awesome
Programming Languages
PHP
CMS
WordPress
Analytics & Marketing
Google Analytics
Performance
Lazy Loading, Priority Hints
Web Standards
Twitter Cards
Traffic & Audience
tubulis.com receives approximately 13.5K monthly visitors and ranks #1,736,577 globally. The website has a bounce rate of 32% with visitors viewing an average of 2.1 pages per visit. Users spend an average of 3:15 on the site.
The majority of tubulis.com's traffic comes from undefined, undefined, .
Frequently Asked Questions
What is tubulis.com?
What technologies does tubulis.com use?
How do I contact tubulis.com?
What are tubulis.com's social media accounts?
How popular is tubulis.com?
Related Searches
This page provides publicly available information about tubulis.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit tubulis.com directly at https://tubulis.com.